Rhythm Pharmaceuticals, Inc. (FRA:1RV)

Market Cap	5.76B +79.7%
Revenue (ttm)	148.58M +54.9%
Net Income	-168.51M
EPS	-2.65
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	86.50
Previous Close	83.00
Day's Range	86.50 - 86.50
52-Week Range	41.00 - 99.00
Beta	n/a
RSI	45.22
Earnings Date	Feb 24, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 283
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1RV

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Financial numbers in USD